Eyebiotech Limited (EyeBio) is a clinical-stage biotechnology company specializing in ophthalmology, focused on developing therapies to protect, restore, and improve vision in patients with sight-threatening retinal diseases such as diabetic macular edema (DME), neovascular age-related macular degeneration (NVAMD), and retinal vein occlusion.
Founded in 2021 with operations in the US and UK, EyeBio was acquired by Merck in 2024 and now operates as a wholly-owned subsidiary. Its pipeline features innovative biologics targeting retinal vascular leakage, including lead candidate Restoret (MK-3000/EYE103), a tetravalent tri-specific Wnt pathway agonist in Phase 2b/3 trials (e.g., BRUNELLO for DME). Another key asset is Tiespectus (MK-8748/EYE201), a bispecific Tie2 agonist/VEGF inhibitor in Phase 1/2a (e.g., RIOJA, MALBEC) for NVAMD and other indications, with pivotal trials planned.
